PTC Therapeutics and Novartis Share Votoplam Study Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PTCT?
Source: Newsfilter
PTC Therapeutics' stock fell 7.93% as it crossed below the 5-day SMA amid mixed market conditions, with the Nasdaq-100 up 0.17% and the S&P 500 down 0.35%.
The decline in PTC's stock comes despite the announcement of a webcast on April 28 to present results from the 24-month interim analysis of the PIVOT-HD study for Votoplam, a treatment for Huntington's disease. This study supports Novartis's Phase 3 INVEST-HD study, indicating a strong partnership and potential for accelerated clinical development. The collaboration with Novartis, which has taken on the responsibility for Votoplam's development and commercialization, highlights the importance of this drug in addressing a critical unmet medical need.
The implications of this partnership and the ongoing clinical trials are significant, as successful results could lead to new treatment options for Huntington's disease patients, potentially enhancing PTC's market position. However, the current stock decline suggests investor caution as they await further data and market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTCT
Wall Street analysts forecast PTCT stock price to rise
14 Analyst Rating
8 Buy
5 Hold
1 Sell
Moderate Buy
Current: 65.060
Low
54.00
Averages
78.18
High
118.00
Current: 65.060
Low
54.00
Averages
78.18
High
118.00
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PTC Therapeutics Reveals Long-Term Results for Votoplam in Huntington's Disease
- Results Presentation: PTC Therapeutics will present the 24-month interim results of its PIVOT-HD study during a webcast today, showcasing the long-term effects of the experimental treatment Votoplam on Huntington's disease patients, which is expected to provide crucial data for future FDA discussions.
- Clinical Trial Background: The PIVOT-HD study initially lasted 12 months and was placebo-controlled, evaluating the effects of Votoplam in Stage 2 and Stage 3 Huntington's disease patients, focusing on reductions in HTT protein, safety outcomes, and changes in disease-related biomarkers.
- Drug Mechanism Analysis: Votoplam is a small-molecule therapy designed to lower the production of mutant HTT protein by modifying RNA splicing, derived from PTC's splicing platform, which shares a similar technological background with Evrysdi, indicating its potential in the treatment landscape.
- Market Performance Overview: PTC Therapeutics' stock has traded between $35.95 and $87.50 over the past year, currently priced at $67.63, down 2.30% from the previous trading day, reflecting market caution and interest in the new therapy's prospects.
See More
PTC and Novartis Advance Huntington's Disease Research with Votoplam
- Clinical Trial Progress: PTC Therapeutics will host a webcast on April 28 to share results from the 24-month interim analysis of the PIVOT-HD study, indicating that long-term data for votoplam supports Novartis's Phase 3 INVEST-HD study, potentially accelerating subsequent clinical development.
- Study Design Details: The PIVOT-HD trial was initially a 12-month placebo-controlled study assessing the pharmacodynamic effects and safety of votoplam at 5mg and 10mg doses, with primary endpoints focused on blood Huntingtin reduction at 12 weeks, influencing future patient selection for studies.
- Strengthened Partnership: Since partnering with Novartis in December 2024, Novartis has taken on the responsibility for the development, manufacturing, and commercialization of votoplam, showcasing the potential for deep collaboration in Huntington's disease treatment.
- Market Outlook Analysis: Huntington's disease is a fatal hereditary condition with no current cure; if PTC's votoplam proves successful, it could provide new treatment options for patients, representing significant market potential.
See More
PTC and Novartis Announce Votoplam Study Progress
- Clinical Research Update: PTC Therapeutics will host a webcast on April 28 to share results from the 24-month interim analysis of Votoplam, indicating its potential in treating Huntington's disease and possibly advancing subsequent research efforts.
- Strengthened Partnership: Novartis highlighted in its quarterly earnings call that long-term data from Votoplam supports the initiation of the Phase 3 INVEST-HD study, demonstrating a close collaboration between the two companies in the Huntington's disease treatment space, which may expedite the drug's market entry.
- Optimized Study Design: The PIVOT-HD study was initially a 12-month placebo-controlled trial, later adding a Stage 3 cohort to better identify the optimal study population for future research, reflecting a deep commitment to patient demographics and scientific rigor.
- Innovative Drug Mechanism: Votoplam, as a small molecule splicing modifier, reduces harmful protein levels by promoting HTT mRNA degradation, showcasing its unique mechanism in Huntington's disease treatment and potentially offering new therapeutic options for patients.
See More
PTC Therapeutics Approves Stock Options and RSUs for New Hire
- Stock Option Grant: On April 13, 2026, PTC Therapeutics approved the grant of 1,155 stock options and 925 restricted stock units (RSUs) to a new non-executive employee, emphasizing the company's commitment to attracting talent.
- Exercise Price Setting: The exercise price for all stock options is set at $70.42 per share, the closing price on the grant date, reflecting the company's confidence in future stock performance while providing potential economic incentives for employees.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting in the first year and 6.25% every three months thereafter, ensuring employee retention and loyalty through continued service with the company.
- RSU Vesting Plan: The RSUs will also vest over four years, with 25% vesting annually, a strategy that not only helps attract and retain key talent but also enhances employee motivation and overall company performance through long-term incentives.
See More
PTC Therapeutics Approves Stock Options and RSUs for New Hire
- Stock Option Grant: On April 13, 2026, PTC Therapeutics approved the issuance of 1,155 stock options and 925 restricted stock units (RSUs) to a new non-executive employee, demonstrating the company's commitment to attracting talent and enhancing its workforce.
- Exercise Price: The exercise price for all stock options is set at $70.42 per share, which aligns with the closing price on the grant date, ensuring that employee interests are aligned with shareholder value, thereby motivating performance.
- Grant Structure: The stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and 6.25% every three months thereafter, designed to encourage long-term retention and sustained contributions from the employee.
- RSU Vesting Schedule: The RSUs also vest over four years with 25% vesting annually, which not only enhances employee loyalty but also positions the company to attract more top talent in the future, further driving growth.
See More
PTC Appoints Biotechnology Investment Banker to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition is anticipated to provide PTC with deep industry insights and strategic guidance, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC CEO Matthew B. Klein stated that Chutter was a trusted advisor to PTC, and her broad vision and successful company-building experience will make her a valued board member, driving the company forward.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation in recent years, noting that the company has become a strong and execution-oriented biotech firm well-positioned for future success, indicating a positive outlook for the company in the industry.
See More
PTC Therapeutics Reveals Long-Term Results for Votoplam in Huntington's Disease
- Results Presentation: PTC Therapeutics will present the 24-month interim results of its PIVOT-HD study during a webcast today, showcasing the long-term effects of the experimental treatment Votoplam on Huntington's disease patients, which is expected to provide crucial data for future FDA discussions.
- Clinical Trial Background: The PIVOT-HD study initially lasted 12 months and was placebo-controlled, evaluating the effects of Votoplam in Stage 2 and Stage 3 Huntington's disease patients, focusing on reductions in HTT protein, safety outcomes, and changes in disease-related biomarkers.
- Drug Mechanism Analysis: Votoplam is a small-molecule therapy designed to lower the production of mutant HTT protein by modifying RNA splicing, derived from PTC's splicing platform, which shares a similar technological background with Evrysdi, indicating its potential in the treatment landscape.
- Market Performance Overview: PTC Therapeutics' stock has traded between $35.95 and $87.50 over the past year, currently priced at $67.63, down 2.30% from the previous trading day, reflecting market caution and interest in the new therapy's prospects.
See More
PTC and Novartis Advance Huntington's Disease Research with Votoplam
- Clinical Trial Progress: PTC Therapeutics will host a webcast on April 28 to share results from the 24-month interim analysis of the PIVOT-HD study, indicating that long-term data for votoplam supports Novartis's Phase 3 INVEST-HD study, potentially accelerating subsequent clinical development.
- Study Design Details: The PIVOT-HD trial was initially a 12-month placebo-controlled study assessing the pharmacodynamic effects and safety of votoplam at 5mg and 10mg doses, with primary endpoints focused on blood Huntingtin reduction at 12 weeks, influencing future patient selection for studies.
- Strengthened Partnership: Since partnering with Novartis in December 2024, Novartis has taken on the responsibility for the development, manufacturing, and commercialization of votoplam, showcasing the potential for deep collaboration in Huntington's disease treatment.
- Market Outlook Analysis: Huntington's disease is a fatal hereditary condition with no current cure; if PTC's votoplam proves successful, it could provide new treatment options for patients, representing significant market potential.
See More
PTC and Novartis Announce Votoplam Study Progress
- Clinical Research Update: PTC Therapeutics will host a webcast on April 28 to share results from the 24-month interim analysis of Votoplam, indicating its potential in treating Huntington's disease and possibly advancing subsequent research efforts.
- Strengthened Partnership: Novartis highlighted in its quarterly earnings call that long-term data from Votoplam supports the initiation of the Phase 3 INVEST-HD study, demonstrating a close collaboration between the two companies in the Huntington's disease treatment space, which may expedite the drug's market entry.
- Optimized Study Design: The PIVOT-HD study was initially a 12-month placebo-controlled trial, later adding a Stage 3 cohort to better identify the optimal study population for future research, reflecting a deep commitment to patient demographics and scientific rigor.
- Innovative Drug Mechanism: Votoplam, as a small molecule splicing modifier, reduces harmful protein levels by promoting HTT mRNA degradation, showcasing its unique mechanism in Huntington's disease treatment and potentially offering new therapeutic options for patients.
See More
PTC Therapeutics Approves Stock Options and RSUs for New Hire
- Stock Option Grant: On April 13, 2026, PTC Therapeutics approved the grant of 1,155 stock options and 925 restricted stock units (RSUs) to a new non-executive employee, emphasizing the company's commitment to attracting talent.
- Exercise Price Setting: The exercise price for all stock options is set at $70.42 per share, the closing price on the grant date, reflecting the company's confidence in future stock performance while providing potential economic incentives for employees.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting in the first year and 6.25% every three months thereafter, ensuring employee retention and loyalty through continued service with the company.
- RSU Vesting Plan: The RSUs will also vest over four years, with 25% vesting annually, a strategy that not only helps attract and retain key talent but also enhances employee motivation and overall company performance through long-term incentives.
See More
PTC Therapeutics Approves Stock Options and RSUs for New Hire
- Stock Option Grant: On April 13, 2026, PTC Therapeutics approved the issuance of 1,155 stock options and 925 restricted stock units (RSUs) to a new non-executive employee, demonstrating the company's commitment to attracting talent and enhancing its workforce.
- Exercise Price: The exercise price for all stock options is set at $70.42 per share, which aligns with the closing price on the grant date, ensuring that employee interests are aligned with shareholder value, thereby motivating performance.
- Grant Structure: The stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and 6.25% every three months thereafter, designed to encourage long-term retention and sustained contributions from the employee.
- RSU Vesting Schedule: The RSUs also vest over four years with 25% vesting annually, which not only enhances employee loyalty but also positions the company to attract more top talent in the future, further driving growth.
See More
PTC Appoints Biotechnology Investment Banker to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition is anticipated to provide PTC with deep industry insights and strategic guidance, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC CEO Matthew B. Klein stated that Chutter was a trusted advisor to PTC, and her broad vision and successful company-building experience will make her a valued board member, driving the company forward.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation in recent years, noting that the company has become a strong and execution-oriented biotech firm well-positioned for future success, indicating a positive outlook for the company in the industry.
See More
